Canada biosimilar contract
manufacturing market is anticipated to witness impressive growth during the
forecast period. This can be ascribed to the rising
prevalence of chronic diseases such as cancer and cardiovascular diseases along
with the growing awareness about use of advance biosimilar contract
manufacturing for the early diagnosis of different types of cancers across the
region. Also, growing demand for biosimilars for their cost effectiveness is
anticipated to drive the growth of Canada biosimilar contract manufacturing
market during the forecast period. Also, regulatory approvals and other
regulations favouring biosimilars adoption in the region is expected to create
lucrative growth of Canada biosimilar contract manufacturing market during the
forecast period. Similarly, complexities in the development and manufacturing
of biosimilars and resistance from reference biologic manufacturers is
anticipated to restrain the growth of Canada biosimilar contract manufacturing
market over the years.
Patent Expiration
Patent expiration can be a significant
driver of the growth of the biosimilar contract manufacturing market in Canada.
When the patents on biologic drugs expire, it allows other companies to develop
and manufacture biosimilars, which are like the reference product in terms of
safety and efficacy but are typically less expensive. Patent expiration creates
an opportunity for biosimilar manufacturers to enter the market and offer a
more affordable alternative to the reference product. Biosimilars offer cost
savings for patients and healthcare providers, making them an attractive option
in a healthcare system that is increasingly focused on cost-effectiveness. The
expiry of patents on biologics is expected to increase in the coming years,
creating a significant opportunity for the biosimilar contract manufacturing
market in Canada. Many of the top-selling biologics are expected to lose patent
protection in the next few years, providing an opportunity for biosimilar
manufacturers to enter the market and offer more affordable treatment options.
The Canadian government has also implemented policies to encourage the
development and manufacturing of biosimilars, recognizing the potential cost
savings and increased access to treatments that these drugs can offer. For
example, the government has implemented a regulatory framework for biosimilars
that allows for an abbreviated approval process, making it easier and more
cost-effective for biosimilars to be brought to market.
Cost Savings
Cost savings is a significant factor
driving the growth of the biosimilar contract manufacturing market in Canada.
Biosimilars are typically less expensive than their reference biologic
products, offering cost savings for patients and healthcare providers. This
cost-effectiveness is driving the demand for biosimilars, which is expected to
continue to increase in the coming years. The Canadian healthcare system is
facing increasing pressure to provide cost-effective treatments to patients.
Biosimilars offer a more affordable alternative to biologics, which can be expensive
and often inaccessible to many patients. As a result, the demand for
biosimilars is expected to increase as patients and healthcare providers seek
more cost-effective treatment options. The cost savings associated with
biosimilars are also driving the growth of the biosimilar contract
manufacturing market in Canada. Contract manufacturers can provide
cost-effective production solutions, enabling biosimilar manufacturers to
produce these drugs more efficiently and at a lower cost. The Canadian government
has also implemented policies to encourage the development and use of
biosimilars, recognizing the potential cost savings and increased access to
treatments that these drugs can offer. For example, the government has
implemented policies to increase the use of biosimilars in the public drug
plan, encouraging healthcare providers to prescribe these drugs.
Regulatory Environment
The regulatory environment plays a
crucial role in the growth of the biosimilar contract manufacturing market in
Canada. Biosimilars are highly regulated drugs, and the regulatory framework in
Canada has a significant impact on the development, manufacturing, and
commercialization of these drugs. The Canadian government has implemented a
regulatory framework for biosimilars that allows for an abbreviated approval
process, making it easier and more cost-effective for biosimilars to be brought
to market. The regulatory framework is designed to ensure that biosimilars are
safe and effective, and that they meet the same quality standards as their
reference biologic products. The regulatory framework in Canada also provides
opportunities for biosimilar manufacturers to compete with reference biologic
products. The government has implemented policies to encourage the use of
biosimilars, including the implementation of biosimilar switching policies that
allow patients to switch from reference biologics to biosimilars. The
regulatory environment also influences the growth of the biosimilar contract
manufacturing market in Canada by ensuring that biosimilar manufacturers have
access to the necessary resources to develop and manufacture these drugs. The
government has implemented policies to support the development of biosimilars,
including funding for research and development, and tax incentives for
biosimilar manufacturers.
Growing Demand for Affordable Treatment
The growing demand for affordable
treatment is a significant driver of the biosimilar contract manufacturing
market in Canada. Biosimilars offer a more affordable alternative to biologic
drugs, which can be expensive and often inaccessible to many patients. As a
result, the demand for biosimilars is increasing in Canada, driven by patients
and healthcare providers seeking more cost-effective treatment options. The
high cost of biologics has become a significant challenge for the Canadian
healthcare system, leading to increasing pressure to provide cost-effective
treatments to patients. Biosimilars offer a more affordable alternative,
providing patients with access to effective treatments while reducing the
overall cost burden on the healthcare system. This is driving the demand for
biosimilars in Canada, which is expected to continue to increase in the coming
years. The growing demand for affordable treatment is also driving the growth
of the biosimilar contract manufacturing market in Canada. Contract
manufacturers can provide cost-effective production solutions, enabling
biosimilar manufacturers to produce these drugs more efficiently and at a lower
cost. This is allowing biosimilar manufacturers to offer more affordable
treatment options to patients, while also increasing their profit margins. In
addition, the Canadian government has implemented policies to encourage the
development and use of biosimilars, recognizing the potential cost savings and
increased access to treatments that these drugs can offer. For example, the
government has implemented policies to increase the use of biosimilars in the
public drug plan, encouraging healthcare providers to prescribe these drugs.
Download Free Sample Report
Technological Advancements
Technological advancements have a
significant impact on the growth of the biosimilar contract manufacturing
market in Canada. As the demand for biosimilars continues to increase,
manufacturers are seeking new and innovative manufacturing technologies to
produce these drugs more efficiently and cost-effectively. Advances in
bioprocessing technologies have made it possible to produce biosimilars with
higher purity and yield, which reduces the cost of production. Process optimization
allows manufacturers to achieve higher production volumes and quality
standards, making the production of biosimilars more efficient and
cost-effective. The development of new analytical tools and techniques has
allowed for more accurate characterization of biosimilars, ensuring that they
meet the same quality standards as their reference biologic products. This is
critical for biosimilar manufacturers, as it enables them to demonstrate the
safety and efficacy of their products to regulatory authorities. Continuous
manufacturing is a new manufacturing approach that allows for the continuous
production of biologics, reducing the time and cost associated with traditional
batch manufacturing. This technology is increasingly being used in the
biosimilar contract manufacturing market in Canada, as it enables manufacturers
to produce high-quality biosimilars more efficiently and at a lower cost.
Advances in automation technology have made it possible to automate many
aspects of biologic production, reducing the need for manual labor and
improving process efficiency. Automation has the potential to significantly
reduce the cost of production for biosimilars, making them more affordable for
patients.
Recent Developments
- Ruxience:
In August 2020, Pfizer Canada announced the launch of Ruxience
(rituximab), a biosimilar of the biologic drug Rituxan (rituximab).
Ruxience is indicated for the treatment of non-Hodgkin's lymphoma, chronic
lymphocytic leukemia, and rheumatoid arthritis.
- Hadlima:
In February 2020, Samsung Bioepis Canada announced the launch of Hadlima
(adalimumab), a biosimilar of the biologic drug Humira (adalimumab).
Hadlima is indicated for the treatment of rheumatoid arthritis, psoriatic
arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis,
and plaque psoriasis.
- Brenzys:
In February 2019, Merck Canada announced the launch of Brenzys
(etanercept), a biosimilar of the biologic drug Enbrel (etanercept).
Brenzys is indicated for the treatment of rheumatoid arthritis, psoriatic
arthritis, ankylosing spondylitis, and plaque psoriasis.
Market
Segmentation
Canada biosimilar contract manufacturing
market can be segmented by product, technology, application, and region. Based
on product, Canada biosimilar contract manufacturing market can be divided into recombinant non-glycosylated proteins and recombinant
glycosylated proteins. Based on technology, Canada biosimilar contract
manufacturing market can be divided into mammalian and non-mammalian. Based on
application, Canada biosimilar contract manufacturing market can be grouped
into oncology, blood disorders, growth hormonal deficiency, chronic &
autoimmune disorders, rheumatoid arthritis, and others. Regionally, Canada
biosimilar contract manufacturing Market can be categorized into Ontario, Quebec,
Alberta, British Columbia and Saskatchewan and Manitoba.
Market Players
Catalent Ontario Ltd, Alcami Corp.,
Almac Group Inc., Lonza Canada Inc, Biocon Ltd., Avid Bioservices Inc., and Wuxi
Biologics Cayman Inc. are some of the leading players operating in the Canada biosimilar
contract manufacturing market.
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 –
2021
|
|
Estimated Year
|
2023
|
|
Forecast
Period
|
2024
– 2028
|
|
Quantitative Units
|
Revenue
in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments Covered
|
Product
Technology
Application
Region
|
|
Regional
Scope
|
Ontario
region; Quebec region; Alberta region; British Columbia region; Saskatchewan
and Manitoba region; Rest of Canada
|
|
Key Companies Profiled
|
Catalent
Ontario Ltd, Alcami Corp., Almac Group Inc., Lonza Canada Inc, Biocon Ltd.,
Avid Bioservices Inc., Wuxi Biologics Cayman Inc.
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country, regional
& segment scope.
|
|
Pricing and Purchase Options
|
Avail
customized purchase options to meet your exact research needs. Explore purchase options
|
|
Delivery
Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report
Scope:
In this
report, the Canada biosimilar contract manufacturing market has been segmented
into the following categories, in addition to the industry trends which have
also been detailed below:
- Canada Biosimilar Contract Manufacturing Market,
By Product:
o Recombinant Non-glycosylated Proteins
o Recombinant Glycosylated Proteins
- Canada Biosimilar Contract Manufacturing Market,
By Technology:
o
Mammalian
o
Non-Mammalian
- Canada Biosimilar Contract Manufacturing Market,
By Application:
o
Oncology
o
Blood Disorders
o
Growth Hormonal Deficiency
o
Chronic & Autoimmune Disorders
o
Rheumatoid Arthritis
o
Others
- Canada Biosimilar Contract Manufacturing Market,
By Region:
o
Ontario
region
o Quebec region
o Alberta region
o British Columbia region
o Saskatchewan and Manitoba region
o Rest of Canada
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present Canada biosimilar contract
manufacturing market.
Available
Customizations:
With the
given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of additional
market players (up to five).
Canada biosimilar contract manufacturing market is
an upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]